Page 1

Exhibit 99.1 Press Release Bio - Rad Reports Second - Quarter 2021 Financial Results HERCULES , Calif . - July 29 , 2021 - Bio - Rad Laboratories , Inc. ( NYSE : BIO and BIOb ) , a global leader of life science research and clinical diagnostic products , today announced financial results for the second quarter ended June 30 , 2021 . Second - quarter 2021 net sales were $ 715.9 million , an increase of 33.4 percent compared to $ 536.9 million reported for the second quarter of 2020. On a currency - neutral basis , quarterly sales increased 27.5 percent compared to the same period in 2020. Second - quarter gross margin was 56.1 percent compared to 54.6 percent during the second quarter in 2020 . Life Science segment net sales for the second quarter of 2021 were $ 334.2 million , an increase of 32.6 percent compared to the same quarter last year . On a currency - neutral basis , sales increased 27.1 percent compared to the same period in 2020 . Currency - neutral sales increased across nearly all life science research product lines but were primarily driven by growth in our Western Blotting , Droplet Digital PCRⓇ , qPCR , and Process Media product lines . All regions experienced strong currency- neutral sales growth compared to the second quarter of 2020 . Clinical Diagnostics segment sales for the second quarter of 2021 were $ 380.2 million , an increase of 34.3 percent compared to the same period last year . On a currency - neutral basis , sales increased 28.0 percent compared to the second quarter in 2020 . The currency - neutral sales increase was primarily driven by the ongoing recovery across product lines in all regions . Income from operations during the second quarter of 2021 was $ 124.8 million versus $ 51.7 million during the same quarter last year . Net income for the second quarter of 2021 was $ 914.1 million , or $ 30.32 per share , on a diluted basis , versus $ 966.4 million , or $ 32.15 per share , on a diluted basis , during the same period in 2020. Net income for the second quarter of 2021 and 2020 was impacted by the recognition of changes in the fair market value of equity securities , primarily related to the holdings of our investment in Sartorius AG . The effective tax rate for the second quarter of 2021 was 21.0 percent , compared to 22.4 percent for the same period in 2020. The tax rates for both periods were driven by the large unrealized gain in equity securities . In addition , the effective income tax rate for the second quarter of 2021 was lower also due to the release of certain tax reserves resulting from the lapse of certain statute of limitations . " Performance in the second quarter for both our Life Science and Clinical Diagnostics segments was strong and ahead of expectations , " said Norman Schwartz , Bio - Rad President and Chief Executive Officer . " We are pleased to see the gradual recovery in our end markets across the business and in all regions after the significant downturn last year with the onset of COVID - 19 . Although the pandemic is still somewhat unpredictable , we have adapted well to the constraints of COVID - 19 and continue to make progress on our core strategies , while supporting our customers and ensuring the safety of our employees , " he said . 1